Asst. Prof. Shilpa Gupta discusses the newly defined criteria for “platinum-ineligibility” in patients with metastatic urothelial cancer on behalf of the Platinum-Ineligibility in Bladder Cancer Working Group.


Newly defined criteria for “platinum-ineligible” patients with metastatic urothelial cancer (mUC)

Asst. Prof. Shilpa Gupta discusses results from the Bladder Cancer Working Group survey study. The aim of the study is to define criteria for “platinum-ineligibility” in patients with metastatic urothelial cancer (mUC). Platinum-ineligible mUC patients are those who are ineligible for cisplatin and carboplatin treatment and therefore have limited treatment options. Other treatments such as pembrolizumab and atezolizumab are available but restricted to patients who are either ‘platinum ineligible’ or who have high PD-L1 expression. Therefore, a definition of platinum-ineligibility is necessary when deciding on patient treatments, and for determining patients eligibility for clinical trials.

Methods for defining platinum ineligibility

Presented are data from two rounds of survey among genitourinary oncologists. The threshold of criteria such as age, ECOG performance status, creatinine clearance, peripheral neuropathy grade, and heart failure classification are assessed as possible defining factors for Platinum-Ineligibility. Prof. Gupta concludes 5 specified criteria, any one of which would class a patient as platinum-ineligible and thus receive immunotherapy in place of cisplatin and carboplatin. The video and slides aim to provide practical guidance for urologists and we hope you find it of use to your clinical practice.

Shilpa Gupta, MD is an Associate Professor in the Division of Hematology, Oncology and Transplantation and the lead for the Phase 1 Interdisciplinary Solid Tumor Program at the Masonic Cancer Center, University of Minnesota, Minneapolis, USA. Prior to joining the University of Minnesota in July 2015, Dr Gupta was faculty in Genitourinary Oncology and Experimental Therapeutics at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida for 4 years. Dr Gupta’s clinical and research interests are to treat patients with genitourinary malignancies and develop novel trials using targeted therapies and immunotherapies. She is currently the Principal investigator of several early and late phase trials in genitourinary oncology. Dr Gupta is passionate about her research and has published her research across a variety of peer-reviewed journals and book chapters. Twitter: @shilpaonc Email:guptash@umn.edu

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

ipcv Interactive Patient Case Video (IPCV)

Episode

1

of 1

episode
Oncology 
Shared decision-making for prostate cancer patients

Early treatment intensification with a PARPi plus ARPI combination

Experts
Prof. Gunhild von Amsberg
Endorsed by
  • clock 25 MIN
  • calendar Sep 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca 
micro-learning Micro learning - Video, slides and more

Module

2

of 2

module
Oncology 
PARP inhibitors in prostate cancer and the rationale behind combination treatment

Module 2 - Evolving landscape of PARPi in mCRPC: Combination with anti-androgens

Experts
Assoc. Prof. Alicia Morgans, Dr Pasquale Rescigno
Endorsed by
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Oct 2023
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca
animated-video Animated Video

Episode

2

of 2

episode
Oncology 
Clinical implementation of testing and PARPis in combination with NHAs

Episode 2: Clinical implementation of testing and PARP inhibitors in combination with NHAs

Experts
Dr Andrew J. Armstrong
Endorsed by
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jul 2023
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca
animated-video Animated Video

Episode

1

of 2

episode
Oncology 
Clinical implementation of testing and PARPi as monotherapy

Episode 1: Clinical implementation of testing and PARPi monotherapy

Experts
Dr Neal Shore
Endorsed by
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jul 2023
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca
podcast Video podcast
Oncology 
Which mCSPC patients benefit from early treatment intensification?

A podcast from GU oncology experts

Experts
Assoc. Prof. Shilpa Gupta, Dr Fabio Schutz
  • download Downloadable
    Resources
  • clock 22 MIN
  • calendar Mar 2023
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer
conference-update Conference update

Episode

4

of 4

episode
Oncology 
Highlights from ESMO 2026

Experts join us at ESMO 2026 to share their insights on new data on GI, liver, lung, breast and GU cancers

Experts
Dr Elizabeth Smyth, Dr Yelena Janjigian, Assoc. Prof. Gerald Prager, Prof. Hong Jae Chon, Assoc. Prof. Lorenza Rimassa, Dr Tom Newsom-Davis, Dr Louise Lim, Dr Komal Jhaveri, Dr Roberto Iacovelli
Endorsed by
  • download Downloadable
    Resources
  • clock 9 MIN
  • calendar Oct 2026
  • Non-accredited Independent Medical Education